Anxiety Disorders, Depression, Stress Disorder
Conditions
Keywords
transdiagnostic, single-session
Brief summary
The goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. The main questions it aims to answer is: * Will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress? * Will the transdiagnostic treatment program decrease transdiagnostic risk factors? * Will the transdiagnostic treatment program decrease the measured risk factors equally? * Will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally? * Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors? * Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms? * Have the participants been able to generalize the skills taught in the program(qualitative)? * Within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?
Detailed description
The study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress. The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions. The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.
Interventions
BEHAVIORALTransdiagnostic single-session treatment
Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
Sponsors
Region Norrbotten
Luleå Tekniska Universitet
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomized controlled trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Meet the criteria for anxiety, mood disorder, or stress diagnosis * Symptoms are mild to moderate in severity
Exclusion criteria
* Already in ongoing psychotherapy * Within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose * Has a comorbid personality disorder * Has a risk of suicide deemed other than low * Has other severe psychological disorders outside the scope of primary care * Is in a severely stressful social situation deemed incompatible with psychotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Generalization | 6 months post-treatment | Qualitative interview with a few selected patients to review their experience of the treatment, its effectiveness and their ability to use the techniques taught. |
| Anxiety, Depression and Stress symptoms post-treatment | 3 weeks post-treatment | Measured using DASS-21 |
| Anxiety, Depression and Stress symptoms follow-up | 6 months post-treatment | Measured using DASS-21 |
| Anxiety sensitivity post-treatment | 3 weeks post-treatment | Measured using BSQ, fear of bodily sensations related to anxiety |
| Anxiety sensitivity follow-up | 6 months post-treatment | Measured using BSQ, fear of bodily sensations related to anxiety |
| Experiential avoidance post-treatment | 3 weeks post-treatment | Measured using AFQ-Y8, psychological flexibility |
| Experiential avoidance follow-up | 6 months post-treatment | Measured using AFQ-Y8, psychological flexibility |
| Mindfulness post-treatment | 3 weeks post-treatment | Measured using FFMQ, mindfulness |
| Mindfulness follow-up | 6 months post-treatment | Measured using FFMQ, mindfulness |
| Alexithymia post-treatment | 3 weeks post-treatment | Measured using TAS-20, mindfulness |
| Alexithymia follow-up | 6 months post-treatment | Measured using TAS-20, mindfulness |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Additional treatment | 6 months post-treatment | It will be recorded if patients sought additional care after single-session treatment as well as type of care. |
Countries
Sweden
Contacts
Primary ContactJohn Näsling, Master
Outcome results
None listed